AAAAAA
Results: 1-25/49
Authors:
Neat, MJ
Foot, N
Jenner, M
Goff, L
Ashcroft, K
Burford, D
Dunham, A
Norton, A
Lister, TA
Fitzgibbon, J
Citation: Mj. Neat et al., Localisation of a novel region of recurrent amplification in, follicular lymphoma to an similar to 6.8 Mb region of 13q32-33, GENE CHROM, 32(3), 2001, pp. 236-243
Authors:
Lillington, DM
Micallef, INM
Carpenter, E
Neat, MJ
Amess, JAL
Matthews, J
Foot, NJ
Young, BD
Lister, TA
Rohatiner, AZS
Citation: Dm. Lillington et al., Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma, J CL ONCOL, 19(9), 2001, pp. 2472-2481
Authors:
Swerdlow, AJ
Schoemaker, MJ
Allerton, R
Horwich, A
Barber, JA
Cunningham, D
Lister, TA
Rohatiner, AZS
Hudson, GV
Williams, MV
Linch, DC
Citation: Aj. Swerdlow et al., Lung cancer after Hodgkin's disease: A nested case-control study of the relation to treatment, J CL ONCOL, 19(6), 2001, pp. 1610-1618
Authors:
Williams, CD
Harrison, CN
Lister, TA
Norton, AJ
Blystad, AK
Coiffier, B
Taghipour, G
Schmitz, N
Goldstone, AH
Citation: Cd. Williams et al., High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: A case-matched study from the European bone marrow transplant registry, J CL ONCOL, 19(3), 2001, pp. 727-735
Authors:
Summers, KE
Goff, LJ
Wilson, AG
Gupta, RK
Lister, TA
Fitzgibbon, J
Citation: Ke. Summers et al., Frequency of the Bcl-2/IgH rearrangement in normal individuals: Implications for the monitoring of disease in patients with follicular lymphoma, J CL ONCOL, 19(2), 2001, pp. 420-424
Authors:
Kaminski, MS
Zelenetz, AD
Press, OW
Saleh, M
Leonard, J
Fehrenbacher, L
Lister, TA
Stagg, RJ
Tidmarsh, GF
Kroll, S
Wahl, RL
Knox, SJ
Vose, JM
Citation: Ms. Kaminski et al., Pivotal study of iodine I 131 Tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas, J CL ONCOL, 19(19), 2001, pp. 3918-3928
Authors:
Lister, TA
Cameron, AC
Hilditch, RW
Citation: Ta. Lister et al., Starspot distributions on XY UMa during 1997-2000 from eclipse mapping, M NOT R AST, 326(4), 2001, pp. 1489-1498
Authors:
Foran, JM
Norton, AJ
Micallef, INM
Taussig, DC
Amess, JAL
Rohatiner, AZS
Lister, TA
Citation: Jm. Foran et al., Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis, BR J HAEM, 114(4), 2001, pp. 881-883
Authors:
Micallef, INM
Rohatiner, AZS
Carter, M
Boyle, M
Slater, S
Amess, JAL
Lister, TA
Citation: Inm. Micallef et al., Long-term outcome of patients surviving for more than ten years following treatment for acute leukaemia, BR J HAEM, 113(2), 2001, pp. 443-445
Authors:
Rohatiner, A
Radford, J
Deakin, D
Earl, H
Love, SB
Price, O
Wilson, A
Lister, TA
Citation: A. Rohatiner et al., A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma, BR J CANC, 85(1), 2001, pp. 29-35
Authors:
Dalley, CD
Lister, TA
Cavenagh, JD
Rohatiner, AZS
Citation: Cd. Dalley et al., Serum LDH, a prognostic factor in elderly patients with acute myelogenous leukaemia, BR J CANC, 84(1), 2001, pp. 147-147
Authors:
Bassan, R
Rohatiner, AZS
Lerede, T
Carter, M
Di Bona, E
Pogliani, E
Rossi, G
Fabris, P
Morandi, S
Lambertenghi-Deliliers, G
Casula, P
Vespignani, M
Lister, TA
Barbui, T
Citation: R. Bassan et al., Early application of anthracyclines in adult acute lymphoblastic leukemia (ALL), HEMAT BLOOD, 40, 2001, pp. 402-413
Authors:
Bassan, R
Rohatiner, AZ
Di Bona, E
Lerede, T
Carter, M
Rambaldi, A
Pogliani, E
Rossi, G
Fabris, P
Morandi, S
Lambertenghi-Deliliers, G
Lister, TA
Barbui, T
Citation: R. Bassan et al., Prognostic factors in Philadelphia plus BCR-ABL plus acute lymphoblastic leukemia, HEMAT BLOOD, 40, 2001, pp. 426-431
Authors:
Rohatiner, AZS
Bassan, R
Raimondi, R
Amess, JAL
Arnott, S
Personen, A
Rodeghiero, F
Barbui, T
Bradburn, MJ
Carter, M
Lister, TA
Citation: Azs. Rohatiner et al., High-dose treatment with autologous bone marrow support as consolidation of first remission in younger patients with acute myelogenous leukaemia, ANN ONCOL, 11(8), 2000, pp. 1007-1015
Authors:
Shamash, J
Walewski, J
Apostolidis, J
Wilson, AM
Foran, JM
Gupta, RK
Rohatiner, AZS
Kelsey, SM
Lister, TA
Citation: J. Shamash et al., Low-dose continuous chemotherapy (LBCMVD-56) for refractory and relapsing lymphoma, ANN ONCOL, 11(7), 2000, pp. 857-860
Authors:
Crawley, CR
Foran, JM
Gupta, RK
Rohatiner, AZS
Summers, K
Matthews, J
Micallef, INM
Radford, JA
Johnson, SA
Johnson, PW
Sweetenham, JW
Lister, TA
Citation: Cr. Crawley et al., A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma, ANN ONCOL, 11(7), 2000, pp. 861-865
Authors:
Shamash, J
Lee, SM
Radford, JA
Rohatiner, AZS
Chang, J
Morgenstern, GR
Scarffe, JH
Deakin, DP
Lister, TA
Citation: J. Shamash et al., Patterns of relapse and subsequent management following high-dose chemotherapy with autologous haematopoietic support in relapsed or refractory Hodgkin's lymphoma: A two centre study, ANN ONCOL, 11(6), 2000, pp. 715-719
Authors:
Foran, JM
Cunningham, D
Coiffier, B
Solal-Celigny, P
Reyes, F
Ghielmini, M
Johnson, PWM
Gisselbrecht, C
Bradburn, M
Matthews, J
Lister, TA
Citation: Jm. Foran et al., Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response, ANN ONCOL, 11, 2000, pp. 117-121
Authors:
Harris, NL
Jaffe, ES
Diebold, J
Flandrin, G
Muller-Hermelink, HK
Vardiman, J
Lister, TA
Bloomfield, CD
Citation: Nl. Harris et al., The World Health Organization classification of hematological malignanciesreport of the Clinical Advisory Committee Meeting, Airlie House, Virginia,November 1997, MOD PATHOL, 13(2), 2000, pp. 193-207
Authors:
Micallef, INM
Lillington, DM
Apostolidis, J
Amess, JAL
Neat, M
Matthews, J
Clark, T
Foran, JM
Salam, A
Lister, TA
Rohatiner, AZS
Citation: Inm. Micallef et al., Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell supportfor lymphoid malignancies, J CL ONCOL, 18(5), 2000, pp. 947-955
Authors:
Swerdlow, AJ
Barber, JA
Hudson, GV
Cunningham, D
Gupta, RK
Hancock, BW
Horwich, A
Lister, TA
Linch, DC
Citation: Aj. Swerdlow et al., Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: The relation to age at treatment, J CL ONCOL, 18(3), 2000, pp. 498-509
Authors:
Apostolidis, J
Gupta, RK
Grenzelias, D
Johnson, PWM
Pappa, VI
Summers, KE
Salam, A
Adams, K
Norton, AJ
Amess, JAL
Matthews, J
Bradburn, M
Lister, TA
Rohatiner, AZS
Citation: J. Apostolidis et al., High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: Long-term clinical and molecular follow-up, J CL ONCOL, 18(3), 2000, pp. 527-536
Authors:
Foran, JM
Rohatiner, AZS
Cunningham, D
Popescu, RA
Solal-Celigny, P
Ghielmini, M
Coiffier, B
Johnson, PWM
Gisselbrecht, C
Reyes, F
Radford, JA
Bessell, EM
Souleau, B
Benzohra, A
Lister, TA
Citation: Jm. Foran et al., European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma, J CL ONCOL, 18(2), 2000, pp. 317-324
Authors:
Fitzgibbon, J
Neat, MJ
Foot, N
Hill, AS
Lister, TA
Gupta, RK
Citation: J. Fitzgibbon et al., Assignment of brain acid soluble protein 1 (BASP1) to human chromosome 5p15.1 -> p14, differential expression in human cancer cell lines as a result of alterations in gene dosage, CYTOG C GEN, 89(3-4), 2000, pp. 147-149
Authors:
Fitzgibbon, J
Neat, MJ
Jones, L
Foot, N
Lister, TA
Gupta, RK
Citation: J. Fitzgibbon et al., Assignment of B-cell lymphoma 6, member B (zinc finger protein) gene (BCL6B) to human chromosome 17p13.1 by in situ hybridization, CYTOG C GEN, 89(3-4), 2000, pp. 218-219